BioMed Research International has retracted the article titled “The Copper Radioisotopes: A Systematic Review with Special Interest to 64Cu” [1]. The article was found to contain a substantial amount of material from the following published articles:(i)Szymański et al. [2], which is cited as reference .(ii)Wadas et al. [3], which is cited as reference .(iii)Carolyn and Ferdani [4], which is cited as reference .(iv)Smith et al. [5], which is cited as reference .
Retracted: The Copper Radioisotopes: A Systematic Review with Special Interest to 64Cu
References
A. Niccoli Asabella, G. L. Cascini, C. Altini, D. Paparella, A. Notaristefano, and G. Rubini, “The copper radioisotopes: a systematic review with special interest to 64Cu,” BioMed Research International, vol. 2014, Article ID 786463, 9 pages, 2014.
View at: Publisher Site | Google ScholarP. Szymański, T. Fraczek, M. Markowicz, and E. Mikiciuk-Olasik, “Development of copper based drugs, radiopharmaceuticals and medical materials,” BioMetals, vol. 25, no. 6, pp. 1089–1112, 2012.
View at: Publisher Site | Google ScholarT. Wadas, E. Wong, G. Weisman, and C. Anderson, “Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals,” Current Pharmaceutical Design, vol. 13, no. 1, pp. 3–16, 2007.
View at: Publisher Site | Google ScholarJ. Carolyn and R. Ferdani, “Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research,” Cancer Biotherapy & Radiopharmaceuticals, 2009.
View at: Publisher Site | Google ScholarN. A. Smith, D. L. Bowers, and D. A. Ehst, “The production, separation, and use of 67Cu for radioimmunotherapy: A review,” Applied Radiation and Isotopes, vol. 70, no. 10, pp. 2377–2383, 2012.
View at: Publisher Site | Google Scholar